Perelman School of Medicine at the University of Pennsylvania

News and Video Search Results

News coverage

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

GlobeNewswire 23 May 2024

· Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients..

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
GlobeNewswire 20 May 2024
Wistar Scientists Identify Pro-aging ‘Sugar Signature’ in the Blood of People Living with HIV
GlobeNewswire 10 Apr 2024
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards
GlobeNewswire 26 Mar 2024
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
GlobeNewswire 25 Mar 2024

0 shares 1 views

You might like

Perelman School of Medicine at the University of Pennsylvania media coverage

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

GlobeNewswire 22 Mar 2024

New studies at Mount Sinai Health System and Penn Medicine investigate how the brain controls movement

NEW YORK, March..

Biotechnology Industry Insights: Comprehensive Report on Collaboration Deals from 2019-2024 Now Available
GlobeNewswire 05 Mar 2024
CorVista Health Announces Anjali Tiku Owens, M.D. Appointment to Medical Advisory Board
Business Wire 23 Jan 2024
Medical group works to combat ‘disastrous consequences of identity politics’ in medicine
CNA 20 Jan 2024
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
GlobeNewswire 07 Jan 2024

Advertisement

More coverage

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

GlobeNewswire 07 Dec 2023

· VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma· Initiating first-in-human Phase 1..

HKUST Holds 31st Congregation Conferring Honorary Doctoral Degrees on Six Distinguished Leaders
PR Newswire Asia 17 Nov 2023
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
GlobeNewswire 17 Nov 2023
mRNA Vaccine Markets, Trends, Opportunities, Competitive Landscape, and Forecasts, 2028
GlobeNewswire 06 Nov 2023
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
GlobeNewswire 01 Nov 2023